Actuate Therapeutics (NASDAQ:ACTU) Now Covered by HC Wainwright

Analysts at HC Wainwright began coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research note issued on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 168.10% from the stock’s previous close.

Actuate Therapeutics Stock Up 0.8 %

Shares of NASDAQ ACTU opened at $7.46 on Monday. Actuate Therapeutics has a 1 year low of $5.51 and a 1 year high of $11.73. The stock’s 50-day simple moving average is $8.15 and its 200-day simple moving average is $8.07.

Institutional Trading of Actuate Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Freestone Capital Holdings LLC bought a new stake in Actuate Therapeutics in the fourth quarter valued at about $80,000. Envestnet Asset Management Inc. bought a new stake in Actuate Therapeutics in the fourth quarter valued at about $83,000. OMERS ADMINISTRATION Corp bought a new stake in Actuate Therapeutics in the fourth quarter valued at about $84,000. Sigma Planning Corp bought a new stake in Actuate Therapeutics in the fourth quarter valued at about $128,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Actuate Therapeutics in the fourth quarter valued at about $130,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.